Royalty Pharma (RPRX) Non Operating Investment Income (2020 - 2021)

Royalty Pharma (RPRX) reported Non Operating Investment Income of $11.8 million for Q3 2021, down 11.6% sequentially from $13.3 million in Q2 2021.

Royalty Pharma (RPRX) Non Operating Investment Income (2020 - 2021) Analysis & Trends

Royalty Pharma (RPRX) has 2 years of Non Operating Investment Income data on file, last reported at $11.8 million in Q3 2021.

For the quarter ending Q3 2021, Non Operating Investment Income changed N/A year-over-year to $11.8 million; the trailing twelve-month figure through Sep 2021 stood at $50.2 million (changed N/A YoY), and the FY2020 full-year result was $20.6 million, changed N/A from the prior year.
Non Operating Investment Income eased to $11.8 million in Q3 2021, from $13.3 million in the prior quarter.
In the past five years, Non Operating Investment Income ranged from a high of $20.6 million in Q4 2020 to a low of $4.6 million in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non Operating Investment Income (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	-
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	-
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	Royalty Pharma	25.70 Bn	25.09 Bn	-	-

Download Data